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In this issue of SJCAPP, Ramstad and colleagues 
review the evidence for psychotic symptoms as an 
adverse effect of methylphenidate treatment in 
children and adolescents with Attention-
Deficit/Hyperactivity Disorder (ADHD) (1). Their 
article summarizes relevant results from two 
Cochrane systematic reviews on methylphenidate 
treatment for ADHD, which are published elsewhere 
(2,3). Based on detailed review of existing studies, 
Ramstad and colleagues report there is not adequate 
evidence to conclude whether or not 
methylphenidate is associated with treatment-
emergent psychotic symptoms, but available 
information suggests psychotic symptoms may occur 
in 1.1 to 2.5 percent of those being treated with 
methylphenidate, so clinicians should be alert to the 
possibility that psychotic symptoms may sometimes 
occur during treatment with methylphenidate.  
Ramstad and colleagues include description of 
randomized as well as non-randomized studies. One 
key part of the review is description of a meta-
analysis including nine placebo-controlled trials. 
Only 10 of 654 methylphenidate-treated patients and 
1 of 508 placebo-treated patients developed 
psychotic symptoms, so the occurrence of psychotic 
symptoms seems to be quite rare, at least during 
short-term treatment with methylphenidate. In the 
meta-analysis, the overall risk ratio for occurrence of 
psychotic symptoms during methylphenidate 
treatment versus placebo is 2.07, with a 95% 
confidence interval of 0.58-7.35. So, while the risk of 
psychotic symptoms in patients taking 
methylphenidate is estimated to be approximately 
double the risk for those taking placebo, the 
confidence interval is quite wide, the association is 
not statistically significant, and no clear conclusion 
can be drawn. Reported results of trial sequential 
analysis suggest the meta-analysis is substantially 
underpowered, so the lack of statistical significance 
cannot be interpreted as absence of risk for psychotic 
symptoms during methylphenidate treatment. 
Ramstad and colleagues also note a number of 
problems with the existing studies, such as high risk 
of bias, potential for confounding factors, and issues 
regarding methods of assessing psychotic symptoms. 
Although no clear conclusions are possible from 
existing studies, there is a signal suggesting the need 
to be alert for possible psychotic symptoms as a side 
effect of methylphenidate, and the problems with 
existing studies suggest a need for further study using 
improved methods and larger sample sizes. One 
important unanswered question is whether 
subgroups of individuals with ADHD are more or 
less susceptible to developing psychotic symptoms as 
a side effect. In addition to acute treatment-emergent 
risk for psychotic symptoms, the long-term effect of 
stimulant use on risk for future psychosis is also 
unclear.  
The review by Ramstad and colleagues has some 
important clinical implications. As there is some 
suggestion that methylphenidate may rarely result in 
psychotic symptoms, it is reasonable and appropriate 
to reduce or stop stimulant medication if psychotic 
symptoms arise during treatment with 
methylphenidate or other stimulant medications. It 
may sometimes be reasonable to re-challenge the 
patient with a stimulant in the future if the stimulant 
previously seemed to have a substantial overall 
benefit and if the psychotic symptoms were mild or 
unclear and did not result in dangerous behavior. 
Extreme caution should be used with any re-
challenge in a patient who developed clear psychotic 
symptoms soon after starting or increasing a 
stimulant medication, especially if delusional thinking 
was involved. Depending on the content of the 
delusions, such thinking may in some cases result in 
illogical and dangerous behavior. Symptoms such as 
vague hallucinations with full insight, with absence of 
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command auditory hallucinations, and no delusional 
ideas regarding the origin of the hallucinations may 
not be as problematic, but these milder psychotic-like 
symptoms are also of concern since it is unclear 
whether allowing such symptoms to continue might 
result in worsening of psychotic symptoms over time 
or other adverse long-term effects.  If psychotic 
symptoms recur with re-challenge, stimulant 
medication may need to be entirely avoided for that 
particular patient. If medication treatment for 
ADHD is indicated but stimulants cannot be 
tolerated without concerning side effects, non-
stimulant ADHD medications can be considered 
(such as guanfacine, clonidine, or atomoxetine). For 
those who cannot tolerate or have poor response to 
multiple ADHD medications, non-pharmacological 
interventions such as behavioral therapies and 
appropriate educational accommodations become 
particularly important. 
In future studies of the relationship between 
stimulant medication and psychosis, a number of 
additional factors need be considered. Although 
most children with ADHD will not develop 
psychotic symptoms or a clear psychotic disorder 
(whether or not they take stimulants), there is 
evidence that ADHD itself may increase the risk for 
psychotic symptoms and even a diagnosis of 
schizophrenia. Difficulties with attention and related 
aspects of cognition can occur as precursors to 
schizophrenia (4). ADHD and other forms of 
psychopathology occur at increased rates in children 
of parents who have schizophrenia spectrum 
disorders (5). Twin and family studies suggest 
substantial genetic overlap between ADHD and 
other psychiatric conditions, including schizophrenia 
(6,7). In one large study, it was determined that 
among patients with schizophrenia and other forms 
of psychosis, treatment with stimulant medication 
was associated with earlier onset of psychosis (8). 
While this could be due to stimulant medication 
causing earlier onset of psychotic symptoms, it could 
also be that the presence of ADHD itself (which 
leads to stimulant treatment) is more directly 
associated with earlier onset of psychosis.  
One growing area of relevant research is the 
pharmacogenetic study of medication responses and 
side effects. A recent review found evidence that 
variants in several genes are associated with 
methylphenidate treatment response in children with 
ADHD (9). Given the rarity of psychotic symptoms 
as a stimulant side effect, very large sample sizes and 
detailed, careful assessment of psychotic-like 
symptoms may be needed to determine whether 
particular genetic variants increase the risk for 
psychotic symptoms in patients treated with 
stimulants for ADHD. One could hypothesize that 
individuals with genetic risk for schizophrenia or 
bipolar disorder might be particularly susceptible, so 
genetic variants that increase risk for these disorders 
may be particularly important to study.  
The following types of future studies may help to 
clarify the relationship between stimulant 
medications and development of psychotic 
symptoms: 1) Large randomized, controlled 
stimulant medication trials including detailed 
assessment of psychotic-like symptoms—from mild 
perceptual disturbances to clear delusional 
thinking—perhaps also including genetic data for 
secondary pharmacogenetic analysis, 2) Randomized, 
controlled stimulant medication trials for ADHD 
symptoms in children with known personal (based 
on genetic tests) or family (based on family history) 
genetic risk for psychosis. Such studies could help 
determine whether stimulants increase (or perhaps 
even decrease) the risk for developing psychosis in 
those who have known genetic risk. These studies 
could perhaps be of much smaller size since the 
incidence of psychotic-like symptoms should be 
higher in those with known genetic risk (whether 
they are taking medication or placebo). Ideally, such 
studies should include long-term follow-up 
considering the average age of psychosis onset in the 
population. 3) Large population-based studies 
investigating the risk for developing schizophrenia or 
psychotic symptoms in ADHD-affected individuals 
who receive stimulants vs. other ADHD treatments 
or no medication. There may be high potential for 
confounding in such studies because individuals with 
more severe ADHD symptoms may have increased 
risk for both schizophrenia and treatment of ADHD 
using medication, but such studies may still provide 
useful information. Despite inherent limitations, 
existing insurance claims and national registry 
databases may be useful for this type of study. 
In conclusion, Ramstad and colleagues report a 
very thorough review of the existing evidence 
regarding psychotic symptoms as an adverse effect of 
methylphenidate. Although the amount and quality 
of existing data does not allow any strong 
conclusions to be drawn regarding the association of 
methylphenidate with treatment-emergent psychotic 
symptoms, clinicians should be alert to the possibility 
that stimulant medications may in rare cases lead to 
psychotic symptoms, and further research is needed 
in order to clarify this possible risk. 
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